{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T07:32:51Z","timestamp":1720337571299},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T00:00:00Z","timestamp":1501632000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00105-017-4021-5","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:46:36Z","timestamp":1501674396000},"page":"702-710","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapie der Mycosis fungoides und des S\u00e9zary-Syndroms"],"prefix":"10.1007","volume":"68","author":[{"given":"J. P.","family":"Nicolay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,2]]},"reference":[{"key":"4021_CR1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et\u00a0al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390","journal-title":"Blood"},{"key":"4021_CR2","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","volume":"113","author":"PT Bradford","year":"2009","unstructured":"Bradford PT, Devesa SS, Anderson WF, Toro JR (2009) Cutaneous lymphoma incidence patterns in the United States: a\u00a0population-based study of 3884 cases. Blood 113:5064\u20135073","journal-title":"Blood"},{"key":"4021_CR3","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ejca.2007.06.015","volume":"43","author":"R Dummer","year":"2007","unstructured":"Dummer R et al (2007) Maintenance therapy in cutaneous T\u2011cell lymphoma: who, when, what? Eur J Cancer 43:2321\u20132329","journal-title":"Eur J Cancer"},{"issue":"Suppl 3","key":"4021_CR4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ddg.12015_5","volume":"11","author":"R Stadler","year":"2013","unstructured":"Stadler R et\u00a0al (2013) Brief S2k guidelines \u2013 cutaneous lymphomas. J\u00a0Dtsch Dermatol Ges 11(Suppl 3):19\u201328, 20\u201330","journal-title":"J Dtsch Dermatol Ges"},{"key":"4021_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F et\u00a0al (2017) European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome \u2013 update 2017. Eur J Cancer 77:57\u201374","journal-title":"Eur J Cancer"},{"key":"4021_CR6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","volume":"128","author":"DL Ramsay","year":"1992","unstructured":"Ramsay DL, Lish KM, Yalowitz CB, Soter NA (1992) Ultraviolet-B phototherapy for early-stage cutaneous T\u2011cell lymphoma. Arch Dermatol 128:931\u2013933","journal-title":"Arch Dermatol"},{"key":"4021_CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-3083.2006.01557.x","volume":"20","author":"F Pavlotsky","year":"2006","unstructured":"Pavlotsky F, Barzilai A, Kasem R, Shpiro D, Trau H (2006) UVB in the management of early stage mycosis fungoides. J\u00a0Eur Acad Dermatol Venereol 20:565\u2013572","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4021_CR8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V","volume":"38","author":"BA Gilchrest","year":"1976","unstructured":"Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB (1976) Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 38:683\u2013689","journal-title":"Cancer"},{"key":"4021_CR9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","volume":"33","author":"JJ Herrmann","year":"1995","unstructured":"Herrmann JJ et al (1995) Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J\u00a0Am Acad Dermatol 33:234\u2013242","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","volume":"141","author":"C Querfeld","year":"2005","unstructured":"Querfeld C et al (2005) Long-term follow-up of patients with early-stage cutaneous T\u2011cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141:305\u2013311","journal-title":"Arch Dermatol"},{"key":"4021_CR11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2133.1992.tb00460.x","volume":"127","author":"P Collins","year":"1992","unstructured":"Collins P, Rogers S (1992) Bath-water compared with oral delivery of 8\u2011methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 127:392\u2013395","journal-title":"Br J Dermatol"},{"key":"4021_CR12","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/archdermatol.2011.2797","volume":"148","author":"N Apisarnthanarax","year":"2012","unstructured":"Apisarnthanarax N et al (2012) Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T\u2011cell lymphoma, mycosis fungoides type. Arch Dermatol 148:613\u2013620","journal-title":"Arch Dermatol"},{"key":"4021_CR13","first-page":"29","volume":"21","author":"R Stadler","year":"2007","unstructured":"Stadler R (2007) Optimal combination with PUVA: rationale and clinical trial update. Oncology 21:29\u201332","journal-title":"Oncology"},{"key":"4021_CR14","first-page":"3578","volume":"92","author":"R Stadler","year":"1998","unstructured":"Stadler R et al (1998) Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T\u2011cell lymphoma stages I and II. Blood 92:3578\u20133581","journal-title":"Blood"},{"key":"4021_CR15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","volume":"20","author":"EA Olsen","year":"1989","unstructured":"Olsen EA et al (1989) Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J\u00a0Am Acad Dermatol 20:395\u2013407","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","volume":"140","author":"O Jumbou","year":"1999","unstructured":"Jumbou O, N\u2019Guyen JM, Tessier MH, Legoux B, Dreno B (1999) Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 140:427\u2013431","journal-title":"Br J Dermatol"},{"key":"4021_CR17","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M et al (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T\u2011cell lymphoma. Arch Dermatol 137:581\u2013593","journal-title":"Arch Dermatol"},{"key":"4021_CR18","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M et al (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T\u2011cell lymphoma: multinational phase II\u2013III trial results. J\u00a0Clin Oncol 19:2456\u20132471","journal-title":"J Clin Oncol"},{"key":"4021_CR19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","volume":"155","author":"C Assaf","year":"2006","unstructured":"Assaf C et al (2006) Minimizing adverse side-effects of oral bexarotene in cutaneous T\u2011cell lymphoma: an expert opinion. Br J Dermatol 155:261\u2013266","journal-title":"Br J Dermatol"},{"key":"4021_CR20","first-page":"428","volume":"8","author":"N Booken","year":"2010","unstructured":"Booken N et al (2010) Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sezary syndrome. J\u00a0Dtsch Dermatol Ges 8:428\u2013438","journal-title":"J Dtsch Dermatol Ges"},{"key":"4021_CR21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10670.x","volume":"166","author":"MR Kamstrup","year":"2012","unstructured":"Kamstrup MR et al (2012) Low-dose total skin electron beam therapy as a\u00a0debulking agent for cutaneous T\u2011cell lymphoma: an open-label prospective phase II study. Br J Dermatol 166:399\u2013404","journal-title":"Br J Dermatol"},{"key":"4021_CR22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","volume":"98","author":"U Wollina","year":"2003","unstructured":"Wollina U et al (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T\u2011cell lymphoma. Cancer 98:993\u20131001","journal-title":"Cancer"},{"key":"4021_CR23","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","volume":"104","author":"E Marchi","year":"2005","unstructured":"Marchi E et al (2005) Gemcitabine as frontline treatment for cutaneous T\u2011cell lymphoma: phase II study of 32 patients. Cancer 104:2437\u20132441","journal-title":"Cancer"},{"key":"4021_CR24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M et al (2006) Phase II evaluation of gemcitabine monotherapy for cutaneous T\u2011cell lymphoma. Clin Lymphoma Myeloma 7:51\u201358","journal-title":"Clin Lymphoma Myeloma"},{"key":"4021_CR25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF et\u00a0al (2015) Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a\u00a0comparative study of systemic therapy. Blood 125:71\u201381","journal-title":"Blood"},{"key":"4021_CR26","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","volume":"321","author":"FJ Kaye","year":"1989","unstructured":"Kaye FJ et al (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N\u00a0Engl J Med 321:1784\u20131790","journal-title":"N Engl J Med"},{"key":"4021_CR27","doi-asserted-by":"crossref","first-page":"205.e1","DOI":"10.1016\/j.jaad.2013.07.049","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T\u2011cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers. J\u00a0Am Acad Dermatol 70:205.e1\u2013205.e6 (quiz 221\u2013202)","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR28","doi-asserted-by":"crossref","first-page":"223.e1","DOI":"10.1016\/j.jaad.2013.08.033","volume":"70","author":"SI Jawed","year":"2014","unstructured":"Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C (2014) Primary cutaneous T\u2011cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J\u00a0Am Acad Dermatol 70:223.e1\u2013223.e17 (quiz 240\u2013222)","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR29","first-page":"256","volume":"14","author":"JP Nicolay","year":"2016","unstructured":"Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Geraud C (2016) Sezary syndrome: old enigmas, new targets. J\u00a0Dtsch Dermatol Ges 14:256\u2013264","journal-title":"J Dtsch Dermatol Ges"},{"key":"4021_CR30","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","volume":"33","author":"JJ Scarisbrick","year":"2015","unstructured":"Scarisbrick JJ et\u00a0al (2015) Cutaneous Lymphoma International Consortium Study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a\u00a0prognostic model. J\u00a0Clin Oncol 33:3766\u20133773","journal-title":"J Clin Oncol"},{"key":"4021_CR31","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E et\u00a0al (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a\u00a0proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713\u20131722","journal-title":"Blood"},{"key":"4021_CR32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2005.00497.x","volume":"75","author":"S Rupoli","year":"2005","unstructured":"Rupoli S et al (2005) Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 75:136\u2013145","journal-title":"Eur J Haematol"},{"key":"4021_CR33","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1468-3083.2010.03732.x","volume":"25","author":"V Nikolaou","year":"2011","unstructured":"Nikolaou V et\u00a0al (2011) PUVA plus interferon alpha2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a\u00a0case series. J\u00a0Eur Acad Dermatol Venereol 25:354\u2013357","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4021_CR34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00105-013-2736-5","volume":"65","author":"JP Nicolay","year":"2014","unstructured":"Nicolay JP, Klemke CD (2014) Management of cutaneous lymphomas. Hautarzt 65:607\u2013613","journal-title":"Hautarzt"},{"key":"4021_CR35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s00105-015-3702-1","volume":"66","author":"U Just","year":"2015","unstructured":"Just U, Knobler R (2015) Update on extracorporeal photopheresis. Hautarzt 66:804\u2013809","journal-title":"Hautarzt"},{"key":"4021_CR36","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1067\/mjd.2000.104852","volume":"43","author":"E Bisaccia","year":"2000","unstructured":"Bisaccia E, Gonzalez J, Palangio M, Schwartz J, Klainer AS (2000) Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T\u2011cell lymphoma: a\u00a09-year retrospective study at a\u00a0single institution. J\u00a0Am Acad Dermatol 43:263\u2013271","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.transci.2014.04.003","volume":"50","author":"F Heshmati","year":"2014","unstructured":"Heshmati F (2014) Updating ECP action mechanisms. Transfus Apher Sci 50:330\u2013339","journal-title":"Transfus Apher Sci"},{"key":"4021_CR38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2014-01-551184","volume":"124","author":"T Krejsgaard","year":"2014","unstructured":"Krejsgaard T et al (2014) Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. Blood 124:761\u2013770","journal-title":"Blood"},{"key":"4021_CR39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","volume":"160","author":"RA Abbott","year":"2009","unstructured":"Abbott RA et\u00a0al (2009) Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol 160:1299\u20131307","journal-title":"Br J Dermatol"},{"issue":"8","key":"4021_CR40","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/jdv.12254","volume":"28","author":"R Piccinno","year":"2014","unstructured":"Piccinno R, Caccialanza M, Cuka E, Recalcati S (2014) Localized conventional radiotherapy in the treatment of Mycosis Fungoides: our experience in 100 patients. J\u00a0Eur Acad Dermatol Venereol 28(8):1040. doi:\n                        10.1111\/jdv.12254","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4021_CR41","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2133.2011.10728.x","volume":"166","author":"DV Chan","year":"2012","unstructured":"Chan DV et al (2012) Radiation therapy in the management of unilesional primary cutaneous T\u2011cell lymphomas. Br J Dermatol 166:1134\u20131137","journal-title":"Br J Dermatol"},{"key":"4021_CR42","doi-asserted-by":"crossref","first-page":"E491","DOI":"10.1002\/ajh.24564","volume":"91","author":"W Hanel","year":"2016","unstructured":"Hanel W et\u00a0al (2016) A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am J Hematol 91:E491\u2013E495","journal-title":"Am J Hematol"},{"key":"4021_CR43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","volume":"34","author":"HS Zackheim","year":"1996","unstructured":"Zackheim HS, Kashani-Sabet M, Hwang ST (1996) Low-dose methotrexate to treat erythrodermic cutaneous T\u2011cell lymphoma: results in twenty-nine patients. J\u00a0Am Acad Dermatol 34:626\u2013631","journal-title":"J Am Acad Dermatol"},{"key":"4021_CR44","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","volume":"30","author":"R Dummer","year":"2012","unstructured":"Dummer R et\u00a0al (2012) Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J\u00a0Clin Oncol 30:4091\u20134097","journal-title":"J Clin Oncol"},{"key":"4021_CR45","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","volume":"144","author":"G Quereux","year":"2008","unstructured":"Quereux G et\u00a0al (2008) Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol 144:727\u2013733","journal-title":"Arch Dermatol"},{"key":"4021_CR46","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL et al (2010) Gemcitabine as single agent in pretreated T\u2011cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860\u2013863","journal-title":"Ann Oncol"},{"key":"4021_CR47","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","volume":"170","author":"A Masson de","year":"2014","unstructured":"de Masson A et al (2014) Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T\u2011cell lymphomas. Br J Dermatol 170:720\u2013724","journal-title":"Br J Dermatol"},{"key":"4021_CR48","first-page":"702","volume":"90","author":"PL Zinzani","year":"2005","unstructured":"Zinzani PL et al (2005) Preliminary observations of a\u00a0phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T\u2011cell lymphoma. Haematologica 90:702\u2013703","journal-title":"Haematologica"},{"key":"4021_CR49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","volume":"92","author":"MG Bernengo","year":"2007","unstructured":"Bernengo MG et al (2007) Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica 92:784\u2013794","journal-title":"Haematologica"},{"key":"4021_CR50","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood-2016-01-694117","volume":"128","author":"JP Nicolay","year":"2016","unstructured":"Nicolay JP et al (2016) Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-kappaB. Blood 128:805\u2013815","journal-title":"Blood"},{"key":"4021_CR51","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/jid.2015.139","volume":"135","author":"D Humme","year":"2015","unstructured":"Humme D et al (2015) Aurora kinase a is upregulated in cutaneous T\u2011cell lymphoma and represents a\u00a0potential therapeutic target. J\u00a0Invest Dermatol 135:2292\u20132300","journal-title":"J Invest Dermatol"},{"issue":"28","key":"4021_CR52","doi-asserted-by":"publisher","first-page":"45687","DOI":"10.18632\/oncotarget.17669","volume":"8","author":"MK Kiessling","year":"2017","unstructured":"Kiessling MK et\u00a0al (2017) NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib. Oncotarget 8(28):45687. doi:\n                        10.18632\/oncotarget.17669","journal-title":"Oncotarget"},{"key":"4021_CR53","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM et\u00a0al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a\u00a0phase Ib study. J\u00a0Clin Oncol 34:2698\u20132704","journal-title":"J Clin Oncol"},{"key":"4021_CR54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000443840","volume":"29","author":"M Beyer","year":"2016","unstructured":"Beyer M et al (2016) The effects of arsenic trioxide in combination with Retinoic acids on cutaneous T\u2011cell Lymphoma cell lines. Skin Pharmacol Physiol 29:63\u201370","journal-title":"Skin Pharmacol Physiol"},{"key":"4021_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","author":"HM Prince","year":"2017","unstructured":"Prince HM et al (2017) Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T\u2011cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. doi:\n                        10.1016\/S0140-6736(17)31266-7","journal-title":"Lancet"},{"key":"4021_CR56","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijd.IJD_73_17","volume":"62","author":"M Bagot","year":"2017","unstructured":"Bagot M (2017) New targeted treatments for cutaneous T\u2011cell lymphomas. Indian J Dermatol 62:142\u2013145","journal-title":"Indian J Dermatol"},{"key":"4021_CR57","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M et al (2014) Multicenter phase II study of mogamulizumab (KW-0761), a\u00a0defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T\u2011cell lymphoma and cutaneous T\u2011cell lymphoma. J\u00a0Clin Oncol 32:1157\u20131163","journal-title":"J Clin Oncol"},{"key":"4021_CR58","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1158\/0008-5472.CAN-14-1456","volume":"74","author":"A Marie-Cardine","year":"2014","unstructured":"Marie-Cardine A et al (2014) IPH4102, a\u00a0humanized KIR3DL2 antibody with potent activity against cutaneous T\u2011cell lymphoma. Cancer Res 74:6060\u20136070","journal-title":"Cancer Res"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-017-4021-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-017-4021-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T22:04:29Z","timestamp":1505167469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-017-4021-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,2]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["4021"],"URL":"https:\/\/doi.org\/10.1007\/s00105-017-4021-5","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,2]]}}}